RegulatoryJun 10, 2026, 06:07 AM
InMed Pharmaceuticals Regains Nasdaq Listing Compliance
AI Summary
InMed Pharmaceuticals Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement for continued listing. The company was previously notified on March 27, 2026, for failing to maintain a $1.00 bid price for 30 consecutive trading days. On June 3, 2026, Nasdaq confirmed that InMed's common shares traded at or above $1.00 for 10 consecutive business days, from May 19, 2026, to June 2, 2026, thereby closing the matter.
Key Highlights
- InMed Pharmaceuticals regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement.
- Nasdaq confirmed on June 3, 2026, that the company's common shares met the $1.00 bid price for 10 consecutive business days.
- The compliance period was from May 19, 2026, through June 2, 2026.
- Nasdaq has closed the matter regarding the company's listing status.
- InMed was initially notified of non-compliance on March 27, 2026.
- The initial non-compliance was due to the bid price being below $1.00 for 30 consecutive trading days.
- The initial non-compliance period was from February 11, 2026, to March 26, 2026.
Price Impact
More from INM